130018-77-8O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1ZKLPARSLTMPFCP-OAQYLSRUSA-N2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid is a diarylmethane.
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Drug-Induced Liver Injury Severity and Toxicity (DILIst)
Levocetirizine
DILI Positive
DOI:10.1016/j.drudis.2019.09.022
R06AE09
R - Respiratory system
QR - Respiratory system
Levocetirizine is a second generation histamine H<sub>1</sub> antagonist used to treat various allergic symptoms. It has a long duration of action as it is generally taken once daily, and a wide therapeutic window as animal studies show the maximal nonlethal dose is over 100x a normal dose. Patients are cautioned to avoid tasks that require complete alertness, avoid alertness, and use caution in patients with factors predisposing urinary retention.
Levocetirizine selectively inhibits histamine H<sub>1</sub> receptors. This action prevents histamine from activating this receptor and causing effects like smooth muscle contraction, increased permeability of vascular endothelium, histidine uptake in basophils, stimulation of cough receptors, and stimulation of flare responses in the nervous system.
Levocetirizine is poorly metabolized with 85.8% of an oral dose being excreted as the unchanged drug. Levocetirizine can be metabolized to a dihydrodiol (M2), an N-oxide (M3), a hydroxymethoxy derivative (M4), a hydroxy derivative (M5), an O-dealkylated derivative (M6), a taurine conjugate (M8), and an N-dealkylated and aromatic hydroxylated derivative (M9). The M5 metabolite can be glucuronidated to form the M1 metabolite and the M9 metabolite can form 4-chloro-4'-hydroxybenzhydryl mercapturates (M10a and M10b).
6U5EA9RT2O
LEVOCETIRIZINE
130018-77-8DTXSID60156294CHEMBL1201191CHEBI:94559Mechanisms of Action [MoA] - Histamine H1 Receptor Antagonists
Established Pharmacologic Class [EPC] - Histamine-1 Receptor Antagonist
Levocetirizine is a Histamine-1 Receptor Antagonist. The mechanism of action of levocetirizine is as a Histamine H1 Receptor Antagonist.
A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment.
Following a 5mg oral dose of levocetirizine, a Cmax of 0.27±0.04µg/mL with a Tmax of 0.75±0.50h. The AUC of levocetirizine is 2.31±0.50µg\*h/mL. Taking levocetirizine with food does not affect the AUC but delays Tmax by 1.25 hours and lowers Cmax by 36%.
168 hours post dose an average of 85.4% of a radiolabeled dose was recovered with an average of 80.8% in the urine and 9.5% in the feces. In the urine, 77% of the dose was recovered as unchanged drug, 0.5% as the M8 and M9 metabolites, 0.4% as the M10a metabolite, 0.4% as the M10b metabolite, 0.3% as the M3 metabolite, 0.3% as the M4 and M5 metabolite, 0.2% as the M2 metabolite, and 0.1% as the M1 metabolite. In the feces, 9.0% of the dose was recovered as unchanged drug, 1.0% as the M4 and M5 metabolite, and 0.1% as the M1 metabolite.
The volume of distribution of levocetirizine is 0.33±0.02L/kg.
The average clearance of levocetirizine is 0.57±0.18mL/min/kg.
BeschreibungThe (R)-enantiomer of the second-generation antihistamine cetirizine, levocetirizine, was first introduced in Germany for seasonal allergic rhinitis (including ocular symptoms), perennial allergic rhinitis and chronic idiopathic urticaria. The dihydrochloride salt can be prepared in four steps from optically active 4-chlorobenzhydrylamine obtained by resolution of its racemate with (+)-tartaric acid. Levocetirizine (eutomer) is a 2-fold more potent H1 antagonist than cetirizine whereas the other enantiomer (distomer) is 10-fold less potent compared to levocetirizine. Pharmacodynamic studies on healthy volunteers showed that compared to cetirizine, half the dose of levocetirizine (5 mg) was necessary to obtain similar inhibitory effects in the skin test of histamine-induced wheal and flare as well as on histamine-induced nasal congestion and nasal resistance. There was no evidence of chiral inversion of levocetirizine in vivo in several species including human. The daily dose of drug is rapidly and extensively absorbed in human. Interestingly, its volume of distribution (0.41 kg/L) is smaller than that of the distomer (0.60 kg/L). The low volume of distribution is considered as favorable for an antihistamine both in terms of efficacy and safety. Due to its high metabolic stability and lack of effect on the activities of the major CYP isoenzymes, levocetirizine is unlikely to cause interactions with other administered drugs. No clinically relevant effect on electrocardiograms of healthy volunteers was detected.
VerwendenA nonsedating type histamine H1-receptor antagonist. A major metabolite of Hydroxyzine. Pharmacological activity resides primarily in the (R)-isomer. Antihystaminic.